PBYI

Puma Biotechnology, Inc.
CAPPED RATING

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Its drug candidates are PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357.

Puma Biotechnology, Inc. (PBYI) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B (3.2) D+ (1.6) B (3.3) B+ (3.7) C+ (2.6) B- (2.9)
2026-11-07 B- (3.1) D+ (1.6) A (4.5) B+ (3.6) C+ (2.7) B- (3.1)
2026-10-31 B- (3.1) C (2.4) B (3.4) A- (4.1) C+ (2.7) B- (3.1)
2026-10-24 B- (3.1) C (2.4) B (3.4) A- (3.9) C+ (2.6) B- (3.1)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe